ADVFN Logo
Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.

ALZN Alzamend Neuro Inc

0.7623
0.02125 (2.87%)
After Hours
Last Updated: 17:51:57
Delayed by 15 minutes

Period:

Draw Mode:

Volume 54,621
Bid Price 0.7417
Ask Price 0.9369
News -
Day High 0.84

Low
0.74

52 Week Range

High
11.91

Day Low 0.741
Company Name Stock Ticker Symbol Market Type
Alzamend Neuro Inc ALZN NASDAQ Common Stock
  Price Change Change Percent Stock Price Last Traded
0.02125 2.87% 0.7623 17:51:57
Open Price Low Price High Price Close Price Prev Close
0.741 0.741 0.84 0.7623 0.74105
Trades Volume VWAP Dollar Volume Avg Volume 52 Week Range
232 54,621 $ 0.7677463 $ 41,935 - 0.74 - 11.91
Last Trade Time Type Quantity Stock Price Currency
17:06:42 2 $ 0.8485 USD

Alzamend Neuro Inc Financials

Market Cap Shares in Issue Float Revenue Profit/Loss EPS PE Ratio
5.41M 7.12M - 0 -14.88M -2.09 -
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- - - -

more financials information »

Alzamend Neuro News

Loading Messages....

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....


No posts yet, be the first! No ALZN Message Board. Create One! See More Posts on ALZN Message Board See More Message Board Posts

Historical ALZN Price Data

Period Open High Low VWAP Avg. Daily Vol Change %
1 Week0.9290.92990.7410.794591937,960-0.1667-17.94%
1 Month0.96591.10170.7410.916762550,079-0.2036-21.08%
3 Months0.931.290.741.0157,190-0.1677-18.03%
6 Months3.123.29850.741.47123,858-2.36-75.57%
1 Year8.809511.910.744.40154,724-8.05-91.35%
3 Years435.00503.250.7442.001,234,717-434.24-99.82%
5 Years435.00503.250.7442.001,234,717-434.24-99.82%

Alzamend Neuro Description

Alzamend Neuro Inc is an early clinical stage biopharmaceutical company. It is focused on developing novel products for the treatment of neurodegenerative diseases and psychiatric disorders, including Alzheimer's. Its mission is to develop and market safe and effective treatments. The company's pipeline consists of two novel therapeutic drug candidates, AL001 - a patented ionic cocrystal technology delivering lithium via a therapeutic combination of lithium, proline and salicylate, and AL002 - a patented method using a mutant-peptide sensitized cell as a cell-based therapeutic vaccine that seeks to restore the ability of a patient's immunological system to combat Alzheimer's.

Your Recent History

Delayed Upgrade Clock